Introduction {#Sec1}
============

Osteogenesis imperfecta (OI) is an inheritable disorder characterized by bone fragility. The fragility of the bones leads to fractures after even mild trauma and subsequent growth restriction. The severity of this condition is highly variable. Patients with OI also suffer from some extraskeletal symptoms including blue or gray discoloration of the sclerae, hearing loss, defective tooth formation (dentinogenesis imperfecta), scoliosis, macrocephaly, barrel chest, and ligamentous laxity \[[@CR1]\].

OI is generally categorized into 4 types according to the Sillence classification, which is based on clinical and radiographic features \[[@CR2]\]. Type I is the mildest, whereas type II is lethal during the neonatal period owing to skeletal deformities and respiratory compromise. Type III is known as the progressive deforming type. Type IV is a moderately severe form, and a type V classification has recently been defined, which is associated with hypertrophic calluses at fracture or surgery sites and intraosseous calcification \[[@CR3]\].

It has been reported that about 85--90% of OI cases are caused by structural or quantitative mutations in *COL1A1* and *COL1A2*, which code for the α1 (I) and α2 (I) chains of type I collagen, respectively. OI type I is related to a quantitative deficiency of structurally normal type I collagen \[[@CR4]\], whereas types II, III, and IV are related to structural defects in either of the 2 chains that form the type I collagen heterodimer \[[@CR5]\]. However, the genotype-phenotype relationship in patients with OI was not completely understood.

Currently, at least 16 genes other than *COL1A1* and *COL1A2* have been reported to be disease-causing genes for OI, including *FKBP10*, *SERPINH1*, *IFITM5*, *SERPINF1*, *CRTAP*, *P3H1*, *PPIB*, *SP7*, *PLOD2*, *BMP1*, *CREB3L1*, *TMEM38B*, *WNT1*, *SPARC*, and *MBTPS2* \[[@CR3], [@CR6]--[@CR8]\]. Because of the large number of genes involved in the pathogenesis of OI and of the large size of *COL1A1* and *COL1A2*, the primary genes causing OI, it is difficult to comprehensively analyze pathogenic mutations using classical Sanger sequencing. Although some reports have described mutations in Japanese patients with OI \[[@CR9], [@CR10]\], genotype-phenotype studies have focused only on *COL1A1* and *COL1A2* in Japan.

In this study, we conducted a comprehensive genetic analysis of Japanese patients with OI using a designed panel of OI-related genes and bone volumes to elucidate the mutation spectrum in this patient population. We also analyzed the mutations and clinical features to clarify the genotype-phenotype relationship.

Subjects and methods {#Sec2}
====================

Subjects {#Sec3}
--------

This study included all individuals with a typical OI phenotype who were evaluated at Osaka University Hospitals, Osaka Women's and Children's Hospital, and Mino City Hospital between 2010 and 2017. Clinical diagnoses of OI were based on a history of more than one fracture following minor trauma, low bone mineral density (BMD), blue sclerae, and a familial history of OI. One of the authors (T.Ki., T.Ku., T.M., Ka.Y., T.Y., N.N., or K.O.) assessed each patient clinically and assigned classifications according to the Sillence classification system.

All 53 individuals reported here were of Japanese descent from unrelated families, residing in Japan, and of Asian ethnicity.

The study was approved by the Institutional Review Board of Osaka University, Osaka Women's and Children's Hospital, and Mino City Hospital. Written informed consent was obtained from patients aged 16 years or older. For individuals under 16 years of age, parental consent was obtained, as well as assent from participants over 8 years old.

Clinical analysis {#Sec4}
-----------------

Patients' heights were measured at each hospital and were converted to age- and sex-specific standard deviation score (SDS) based on reference data from the Japanese Society for Pediatric Endocrinology. The annual fracture rate prior to the initiation of bisphosphonate (BP) treatment was calculated as follows:$$\documentclass[12pt]{minimal}
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BMD at the lumbar spine was measured using dual X-ray absorptiometry (DXA). Areal BMD values were converted to age- and sex-specific SDS using the data of previous studies \[[@CR11]--[@CR13]\].

To calculate the trabecular bone score (TBS), the raw data from the DXA were extracted using TBS iNsight software (v1.9, Medimaps SA, France). TBS was calculated as the mean value of the measurements for L1--L4 at the same region of interest (ROI) as the lumbar spine BMD.

Genetic analysis {#Sec5}
----------------

Targeted next-generation sequencing (NGS) was performed using the Ion Torrent System (Thermo Fisher Scientific, Waltham, MA, USA). A capture panel of targeted DNA was designed to include 15 OI candidate genes, including *COL1A1*, *COL1A2*, *IFITM5*, *SERPINF1*, *CRTAP*, *LEPRE1*, *PPIB*, *SERPINH1*, *FKBP10*, *BMP1*, *SP7*, *TMEM38B*, *WNT1*, *CREB3L1*, and *PLOD2*. This panel also included 19 candidate genes that are associated with bone fragility or Wnt signaling, including *LRP5*, *LRP6*, *TNFRSF11A*, *TNFRSF11B*, *CBS*, *MTHFR*, *MTR*, *WNT4*, *CTNB1*, *WNT16*, *DKK1*, *LRP4*, *SOST*, *WLS*, *SFRP4*, *WNT5B*, *AXIN1*, *RSPO3*, and *TNFSF11.* Custom primers were designed using the Ion AmpliSeq™ Designer (Thermo Fisher Scientific, Waltham, MA, USA) to generate 643 amplicons covering 95.84% of the whole exons of the 34 genes. DNA from blood was amplified to enrich the target exons in the 34 genes in a multiplex polymerase chain reaction (PCR) using the Ion AmpliSeq Library Kit 2.0. The library was prepared by ligating the PCR amplicons into adapters with the addition of barcodes. The library concentration and amplicon sizes were determined using an Agilent BioAnalyzer kit (Agilent Technologies, Santa Clara, CA, USA). Multiplexed barcoded libraries were enriched by clonal amplification using emulsion PCR and were loaded on an Ion 318 Chip (Thermo Fisher Scientific, Waltham, MA, USA). Massively parallel sequencing was carried out on the Ion PGM sequencer (Thermo Fisher Scientific, Waltham, MA, USA). Data analysis and variant calling were performed using Torrent Suite and Ion Reporter software (Thermo Fisher Scientific, Waltham, MA, USA). All of the candidate mutations detected by NGS as well as the uncovered and unread regions with this panel in candidate genes were examined by Sanger sequencing. The amplicons generated with the designed primers were Sanger sequenced using a 3730 DNA analyzer (Applied Biosystems, Foster City, CA, USA).

Statistical analysis {#Sec6}
--------------------

Differences between two groups were analyzed using Student's *t* test. Differences among more than three groups were evaluated using one-way analysis of variance (ANOVA), followed by multiple comparisons using the Tukey-Kramer method. The difference in familial history and the proportion of types of mutations in *COL1A1* and *COL1A2* according to the Sillence classification were analyzed using *χ*^2^ test or Fisher's exact test. Correlations between annual fracture rate, SDS of height, and L1--L4 BMD as well as the number of exons where the mutations were located were examined by simple linear regression analysis. Outliers detected in a robust regression were excluded. All statistical analyses were conducted using JMP Pro software version 13.0.0 (SAS Institute Inc., Cary, NC, USA). *p* \< 0.05 was considered significant.

Results {#Sec7}
=======

Characteristics of the study population {#Sec8}
---------------------------------------

This study included 53 individuals with a clinical diagnosis of OI from unrelated non-consanguineous families. A total of 28 male and 25 female patients were included. The patients' ages ranged from 1 month to 41.7 years at the time of assessment. Familial histories were positive in 29 patients. Patient classification was as follows: type I (*N* = 34), type III (*N* = 9), and type IV (*N* = 10), according to the Sillence classification. Familial histories were positive in 68.8%, 28.6%, and 55.6% of patients with type I, III, and IV OI, respectively, and there was no significant difference according to *χ*^2^ test or Fisher's exact test. The patients' ages were 10.8 ± 12.4, 1.17 ± 1.62, and 3.61 ± 4.19 years for types I, III, and IV, respectively. Although it was not significant, patients with type III at the time of assessment tended to be younger than those with type I according to ANOVA (*p* = 0.060). The SDS of height prior to BP treatment was low (− 1.92 ± 2.20) for all study patients and was significantly lower in type III patients (− 5.53 ± 1.57) than in type I (− 0.96 ± 1.41, *p* \< 0.0001) and type IV (− 2.43 ± 1.78, *p* \< 0.001) patients. Furthermore, type IV patients were significantly shorter than type I patients (*p* \< 0.05). Although the L1--L4 BMD SDS was low (− 2.64 ± 1.55) in all study patients, there was no significant difference among the Sillence classification types. The annual fracture rate was 2.78 ± 6.00 among all study patients, occurring significantly more often in type III patients (10.78 ± 10.37) than in type I (0.54 ± 0.36, *p* \< 0.0001) and type IV (2.88 ± 5.10, *p* \< 0.01) patients. Blue sclerae and dentinogenesis imperfecta were positive in 82.4% (42/51) and 30.0% (15/50) of patients, respectively (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of the study populationSillence classificationIIIIIVTotalSex Male/female19/154/55/528/25Family history Positive/total22/32 (68.8%)2/7 (28.6%)5/9 (55.6%)29/48 (60.4%)Age Years, mean ± SD10.8 ± 12.4(*N* = 34)1.17 ± 1.62^a^(*N* = 8)3.61 ± 4.19(*N* = 9)8.00 ± 11.0(*N* = 51)Height SDS Mean ± SD− 0.96 ± 1.41(*N* = 31)− 5.53 ± 1.57⁎⁎(*N* = 7)− 2.43 ± 1.78⁎ ^††^(*N* = 9)− 1.92 ± 2.20(*N* = 47)L1--L4 BMD SDS Mean ± SD− 2.33 ± 1.47(*N* = 28)− 3.51 ± 2.06(*N* = 3)− 3.42 ± 1.43(*N* = 8)− 2.64 ± 1.55(*N* = 39)Annual fracture rate /Year, mean ± SD0.54 ± 0.36(*N* = 29)10.78 ± 10.4⁎⁎(*N* = 8)2.88 ± 5.10^†^(*N* = 9)2.78 ± 6.00(*N* = 46)Blue sclerae Positive/total30/34 (88.2%)8/8 (100%)4/9 (44.4%)42/51 (82.4%)DI Positive/total4/33 (12.1%)7/8 (87.5%)4/9 (44.4%)15/50 (30.0%)*DI* dentinogenesis imperfecta, *SD* standard deviation, *SDS* standard deviation score^a^*p* = 0.060 vs. type I, ⁎*p* \< 0.05 vs. type I, ⁎⁎*p* \< 0.0001 vs. type I, ^†^*p* \< 0.01 vs. type III, ^††^*p* \< 0.001 vs. type III

Genetic analysis {#Sec9}
----------------

Targeted NGS was performed as the initial diagnostic methodology in 52 patients. In 1 patient, whole-exome NGS was used as the initial diagnostic methodology. Pathogenic or likely pathogenic variants were found in 41 individuals. After the initial diagnostic methodology, whole-exome NGS was performed in 6 individuals in whom the target NGS had not detected disease-causing variants, and it revealed pathogenic mutations in 2 individuals. Overall, pathogenic mutations were detected in 43 out of 53 individuals, all of which were heterozygous. Among the 43 individuals, 40 variants in total were identified, including 28 substitutions (70%), 7 deletions (17%), and 5 duplications (13%). No insertion nor insertion/deletion variants were found in this study. These variants resulted in 12 missense (30%), 7 nonsense (17%), 10 splice site (25%), 7 frameshift (17%), 3 in-frame insertion (8%), and 1 new start codon (3%) mutations. There were no in-frame deletion mutations. Fifteen mutations were novel (10 and 5 in *COL1A1* and *COL1A2*, respectively, comprising 2 missense, 2 nonsense, 5 splice site, 4 frameshift, and 2 in-flame insertion mutations; shown in Table [2](#Tab2){ref-type="table"}), and 25 were known mutations including 7 variants that occurred at the previously reported nucleotide or amino acid but associated with different substitutions (Fig. [1](#Fig1){ref-type="fig"}) (OI database: <https://www.le.ac.uk/ge/collagen/>). Three mutations were shared among unrelated families (*COL1A1*: c.2299G\>A (p.Gly767Ser), c.2461G\>A (p.Gly821Ser), and c.2829+1G\>A).Table 2Novel variants detected by NGSGeneNucleotide changeAmino acid changeMutation typeSillence type*COL1A1*c.387delTp.Pro129Profs\*30FrameshiftI*COL1A1*c.495T\>Gp.Tyr165\*NonsenseI*COL1A1*c.1615-2A\>TSplice siteIII*COL1A1*c.2347G\>Tp.Glu783\*NonsenseI*COL1A1*c.2451+2T\>GSplice siteI*COL1A1*c.2574delTp.Pro859Leufs\*249FrameshiftI*COL1A1*c.2716_2717dupCGp.Gly906Alafs\*40FrameshiftI*COL1A1*c.3112delGp.Glu1038fs\*70FrameshiftI*COL1A1*c.3262-2A\>GSplice siteI*COL1A1*c.3904C\>Tp.Pro1302SerMissenseI*COL1A2*c.395G\>Ap.Arg132HisMissenseI*COL1A2*c.1252-7delTSplice siteI*COL1A2*c.1503+12_14delCACSplice siteIV*COL1A2*c.2419_2427dupp.Pro807_Pro809dupIn-frame insertionIV*COL1A2*c.2952_2960dupp.Gly985_Val987dupIn-frame insertionIFig. 1Mutation spectrum. **a** Frequency of disease-causing variants according to variant type. **b** Frequency of disease-causing variants according to mutation effect. **c** Frequency of novel disease-causing variants according to mutation effect. "Reported" includes variants that are completely matched with the reported one. "Same site variant" represents variants in which other base changes at the same site have been reported. **d** Frequency of disease-causing variants according to affected genes. **e** Frequency of OI according to the Sillence classification for each mutation type on *COL1A1* and *COL1A2*. N.D., not detected; GS, glycine substitution group; TG, truncating group; NTG, non-truncating group; OS, other missense group

Among the 43 individuals in whom mutations were detected, mutations were found on the *COL1A1* (*n* = 30, 69.8%), *COL1A2* (*n* = 12, 27.9%), and *IFITM5* (*n* = 1, 2.3%) genes. No pathogenic mutations were found in 10 individuals (Fig. [1](#Fig1){ref-type="fig"}). A mutation on *IFITM5* (c.-14C\>T), which has been reported to create a new upstream-of-start codon, was reported in one patient \[[@CR14]--[@CR16]\].

Genotype-phenotype correlation in *COL1A1* and *COL1A2* mutations {#Sec10}
-----------------------------------------------------------------

Among 30 individuals harboring the *COL1A1* mutation, 8 glycine substitution (27%), 7 nonsense (23%), 8 splice site (27%), 6 frameshift (20%), and 1 other type of substitution (3%) mutations were detected. No in-frame insertions nor deletions were found on *COL1A1*. Of the *COL1A2* mutations, 5 were glycine substitutions (42%), 3 were splice site mutations (25%), 3 were in-frame insertions (25%), and 1 was another substitution (8%) (Fig. [2](#Fig2){ref-type="fig"}). No nonsense, frameshift, or in-frame deletion mutations were found on *COL1A2* \[[@CR17]\] (Table [3](#Tab3){ref-type="table"}).Fig. 2Gene maps of **a***COL1A1* and **b***COL1A2* exons, with identified mutations and corresponding protein product domains. The numbered box and line between the boxes represent the corresponding exon and intron of the gene. Black, red, and green indicate patients with Sillence types I, III, and IV, respectivelyTable 3Type of *COL1A1* and *COL1A2* mutations*COL1A1*\
*N* = 30 (69.8%)*COL1A2*\
*N* = 12 (27.9%)Glycine substitution8 (27%)5 (42%)Nonsense7 (23%)0 (0%)Splice site8 (27%)3 (25%)Frameshift6 (20%)0 (0%)In-frame insertion0 (0%)3 (25%)Other substitution1 (3%)1 (8%)

To evaluate the contributions of mutations to the phenotype, we distinguished glycine substitutions (GS) from other amino acid substitutions (OS), as glycine substitutions result in severe phenotypes \[[@CR5]\]. We also classified nonsense and frameshift mutations as a truncating group (TG), which has been reported to result in haploinsufficiency and mild phenotypes \[[@CR5], [@CR18]\]. We classified splice site and in-frame insertions as a non-truncating group (NTG), which are known to produce type I collagen with an incomplete structure \[[@CR5], [@CR18]\].

With respect to GS, 2, 7, and 4 patients had Sillence types I, III, and IV, respectively. In the TG, no patient had type III nor IV, but 13 patients had type I. In the NTG, 10, 2, and 2 patients had types I, III, and IV, respectively. Both patients in OS were diagnosed with type I OI. No mutations were detected in 7 and 3 patients with Sillence types I and IV, respectively, and no patient was classified as having type III in this group. The proportion of Sillence type I patients in the entire group was significantly lower in GS than in TG or NTG according to *χ*^2^ test or Fisher's exact test (Fig. [1](#Fig1){ref-type="fig"}).

The annual fracture rates prior to the initiation of BP treatment were 2.83 ± 2.18, 0.47 ± 0.29, 0.71 ± 0.38, and 0.20 ± 0.28 in GS, TG, NTG, and OS, respectively. GS resulted in a significantly greater fracture rate than TG and NTG. We evaluated this in both the *COL1A1* and *COL1A2* mutation groups. Although there were no significant differences in the *COL1A2* mutation group (GS 3.06 ± 2.95, NTG 0.65 ± 0.26, and OS 0.39 ± 0), GS caused a significantly greater fracture rate than that the TG, NTG, and OS within the *COL1A1* mutation group (GS 2.59 ± 1.38, TG 0.47 ± 0.29, NTG 0.76 ± 0.48, OS 0 ± 0). There were no differences between *COL1A1* and *COL1A2* mutations in all mutations (*COL1A1* 1.01 ± 1.12, *COL1A2* 1.72 ± 2.27), in GS (*COL1A1* 2.59 ± 1.38, *COL1A2* 3.06 ± 2.95), nor in NTG (*COL1A1* 0.76 ± 0.48, *COL1A2* 0.65 ± 0.26) (Supplemental Fig. [1](#Fig3){ref-type="supplementary-material"}).

GS resulted in significantly lower SDS of height than TG and NTG before BP treatment (− 4.07 ± 2.19, − 0.93 ± 1.24, − 1.88 ± 2.27, and − 1.73 ± 0.47 in GS, TG, NTG, and OS, respectively). Although no differences were observed in the *COL1A2* mutation group (GS − 3.30 ± 3.17, NTG − 2.90 ± 2.56, OS − 2.06 ± 0), GS on *COL1A1* resulted in a greater severity of short stature than TG and NTG (GS − 4.51 ± 1.53, TG − 0.93 ± 1.24, NTG − 1.00 ± 1.71, OS − 1.40 ± 0). No significant differences were observed between *COL1A1* and *COL1A2* in all mutations (*COL1A1* − 1.89 ± 2.09, *COL1A2* − 2.97 ± 2.53), in GS (*COL1A1* − 4.51 ± 1.53, *COL1A2* − 3.30 ± 3.17), or in NTG (*COL1A1* − 1.00 ± 1.71, *COL1A2* − 2.90 ± 2.56) (Supplemental Fig. [2](#Fig4){ref-type="supplementary-material"}).

Although the L1--L4 BMD SDS prior to the initiation of BP treatment was low in all types of mutations in *COL1A1* and *COL1A2* (GS − 3.12 ± 1.39, TG − 2.32 ± 1.01, NTG − 3.13 ± 1.75, OS − 1.38 ± 0), there was no difference among these mutations. No significant differences were observed even when they were analyzed on each gene (*COL1A1*: GS − 2.71 ± 1.26, TG − 2.32 ± 1.01, NTG − 2.81 ± 2.07; *COL1A2*: GS − 3.53 ± 1.65, NTG − 3.64 ± 1.05, OS − 1.38 ± 0). No gene effect was observed in L1--L4 BMD SDS in all mutations (*COL1A1* − 2.56 ± 1.47, *COL1A2* − 3.35 ± 1.34), in GS (*COL1A1* − 2.71 ± 1.26, *COL1A2* − 3.53 ± 1.65), or in NTG (*COL1A1* − 2.81 ± 2.07, *COL1A2* − 3.64 ± 1.05). The L1--L4 TBS was also evaluated before the initiation of BP treatment, and it was revealed that GS resulted in a significantly lower TBS than NTG (GS 1.11 ± 0.05, TG 1.22 ± 0.10, NTG 1.31 ± 0.09, and OS 1.29 ± 0.10) (Supplemental Fig. [3](#Fig5){ref-type="supplementary-material"}).

Among 42 individuals harboring mutations in *COL1A1* or *COL1A2*, 5, 35, and 2 mutations were located in the N-terminal pro-peptide, triple helix portion, and C-terminal pro-peptide, respectively. No mutations were located in the signal peptide, N-terminal telopeptide, or C-terminal telopeptide. Among 30 individuals with mutations in *COL1A1*, 5, 23, and 2 mutations were located in the N-terminal pro-peptide, triple helix portion, and C-terminal pro-peptide, respectively. All of the mutations in *COL1A2* were located in the triple helix portion (*N* = 12) (Supplemental Table [1](#MOESM7){ref-type="media"}).

The annual fracture rates were 0.57 ± 0.38 (*N* = 4), 1.39 ± 1.69 (*N* = 28), and 0 ± 0 (*N* = 1) in patients with mutations located in the N-terminal pro-peptide, triple helix portion, and C-terminal pro-peptide, respectively. No significant differences in the location of mutations were observed with respect to the annual fracture rate when analyzing *COL1A1* and *COL1A2* together or *COL1A1* alone. There were no significant differences in gene effects with mutations at the triple helix (*COL1A1* 1.18 ± 1.21, *N* = 17; *COL1A2* 1.72 ± 2.27, *N* = 11). There was no correlation between exon number, mutation location, and fracture rate (Supplemental Fig. [4](#Fig6){ref-type="supplementary-material"}).

The SDS of height was − 0.38 ± 1.30 (*N* = 4), − 2.50 ± 2.30 (*N* = 32), and − 1.18 ± 0.32 (*N* = 2) among patients with mutations located in the N-terminal pro-peptide, triple helix portion, and C-terminal pro-peptide, respectively. There were no significant differences in the location of mutations analyzed on *COL1A1* and *COL1A2* together or on *COL1A1* alone, nor was there any gene effect for mutations in the triple helix (*COL1A1* − 2.25 ± 2.19, *N* = 21; *COL1A2* − 2.97 ± 2.53, *N* = 11). There was no correlation between exon number and SDS of height (Supplemental Fig. [5](#Fig7){ref-type="supplementary-material"}).

The L1--L4 BMD SDS was − 1.33 ± 0.86 for the N-terminal pro-peptide (*N* = 3) and − 2.96 ± 1.43 for the triple helix (*N* = 27). No significant differences were observed between these groups. There were significant correlations between L1--L4 BMD SDS and exon numbers analyzed on *COL1A1* and *COL1A2* together (*r*^2^ = 0.176, *p* = 0.02) or on *COL1A2* alone (*r*^2^ = 0.82, *p* = 0.0008) (Supplemental Fig. [6](#Fig8){ref-type="supplementary-material"}).

Discussion {#Sec11}
==========

The results of this study revealed the mutation spectrum in Japanese patients with OI. The targeted NGS of genomic DNA identified disease-causing mutations in 43 out of 53 individuals (81%). We identified 40 variants including 15 novel variants. Although some papers have analyzed *COL1A1* and *COL1A2* mutations in Japanese patients with OI \[[@CR9], [@CR10]\], to the best of our knowledge, our study was the largest and first to comprehensively analyze not only *COL1A1* and *COL1A2* but also other genes associated with OI in Japanese patients.

Consistent with some previous reports, *COL1A1* and *COL1A2* mutations were dominant in our study (97.7%) \[[@CR19]--[@CR21]\]. We detected only 1 mutation on *IFITM5*. Although similar to previous reports indicating that the c.-14C\>T mutation in *IFITM5* was the major variant other than the *COL1A1* and *COL1A2* mutations, the prevalence of this in our population was less than that reported previously \[[@CR19], [@CR21]\].

No biallelic mutations associated with recessive OI were observed in our study. This is totally different from the findings in a report by Essawi et al., which showed that 61% of individuals in their study were affected with autosomal recessive OI in a Palestinian population \[[@CR22]\]. The prevalence of recessive OI may depend on geographical area, as recessive disorders can be more frequent where consanguinity is common.

As reported previously \[[@CR8], [@CR23], [@CR24]\], in our results, GS on *COL1A1* can be clinically distinguishable from other types of mutations since the annual fracture rates and short-stature severity were greater in patients with GS. Although the cause of the short stature derived from the *COL1A1* mutation is not completely understood \[[@CR25]\], it may be secondary to vertebral and long-bone fractures. Alternatively, the mutations may have a direct effect on growth plate activity, as OI is related to disturbances in bone remodeling and regulatory proteins \[[@CR26], [@CR27]\]. Scheiber et al. reported that GS in *COL1A2* induced endoplasmic reticulum stress in the growth plate hypertrophic chondrocytes and contributed to growth deficiency in a mouse model \[[@CR28]\]. These data suggest that a genetic diagnosis is informative and beneficial in patients with OI to appropriately manage their healthcare.

The initial diagnosis of OI is largely based on clinical and radiographic findings that include BMD \[[@CR24]\]. In our study, the L1--L4 BMDs among our patients with OI were lower than those of age-matched healthy children and adolescents in previous reports \[[@CR29]\]. Although BMD provides useful information for diagnosing OI, it is difficult to assess bone strength using BMD \[[@CR30]\], as bone strength is derived from not only BMD but also bone quality, which includes the characteristics of the bone microarchitecture \[[@CR31], [@CR32]\]. The TBS is based on gray-level measurements derived from DXA images. TBS is known to strongly correlate with 3-dimensional microstructure parameters \[[@CR33]\] and predict vertebral and major osteoporotic fractures in patients with osteoporosis, independent of the BMD \[[@CR34], [@CR35]\]. Kocijan et al. reported that adult patients with OI types III and IV had significantly lower TBS values than those with OI type I \[[@CR36]\]. Rehberg et al. reported that TBS increased significantly after treatment with denosumab in children with OI \[[@CR37]\]. Our data suggest that BMD cannot predict bone fragility in patients with OI. However, TBS may be a useful tool for predicting bone strength and fracture risk in patients with OI. More studies are required to clarify this.

Rauch et al. reported that the position of glycine mutations within the α1 and α2 triple helical domains had no obvious relationship with fractures or deformities at birth \[[@CR38]\]. In our study, consistent with previous reports, no relationship was observed between mutation position, annual fracture rate, and SDS of height. Interestingly, among patients with α2 triple helical domain mutations, a significant negative relationship was observed between the position of mutation and the L1--L4 BMD, similar to findings reported by Rauch et al. \[[@CR39]\]. However, it is still difficult to anticipate the severity of bone fragility on the basis of the position of mutations in *COL1A1* and *COL1A2*.

There are some limitations to this study. First, we could not identify any pathogenic mutations in 10 individuals. They may still have a genetic cause for their bone fragility, especially in cases of positive familial histories. As we did not perform the Multiplex Ligation-dependent Probe Amplification method in this study, it is possible that we failed to identify some deletion or duplication mutations. Second, it is possible that we failed to identify intronic mutations located far from a splice site that could have led to splicing defects \[[@CR40]\]. Recently, some variants in several genes including *SPARC* and *MBTPS2* have been identified as disease-causing genes with respect to OI \[[@CR7], [@CR41]\]. We failed to identify pathogenic variants in these genes, as we have not included them. In this study, whole-exome NGS was performed in 6 individuals in whom the target NGS had not detected disease-causing variants, and it revealed pathogenic mutations in 2 individuals. They harbored c.441dupC and c.3262-2A\>G in *COL1A1*. Targeted NGS could fail to detect single-nucleotide duplication or deletion such as c.441dupC mutation, which could be detected by whole-exome NGS. To resolve these issues, we need to update our panel or perform whole-exome sequencing in order to improve accuracy. Finally, few reports have described the Japanese OI mutation spectrum; hence, it is possible that there are unknown gene mutations that can result in OI pathology.

Conclusions {#Sec12}
===========

We identified disease-causing mutations in 81% of our Japanese patients with OI. Most mutations were located on *COL1A1* and *COL1A2* in these patients. No significant difference in L1--L4 BMD SDS was observed among mutations; nonetheless, GS resulted in a significantly greater fracture rate than other mutations. These findings suggest that bone qualities in patients harboring GS were worse than those with other mutations. Considering that TBS was lower in patients with GS, it may be important to measure TBS in order to evaluate their bone qualities. As there is such genotype-phenotype correlation with respect to the severity of bone fragility, comprehensive genetic diagnosis can be useful in treatment and management decision-making for patients with OI.
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Supplemental Fig 1Comparison of annual fracture rate. (**a**) Comparison of fracture rate among the 4 groups with *COL1A1* and *COL1A2* mutations. (**b**) Comparison of fracture rate among the 4 groups with *COL1A1* mutations only. (**c**) Comparison of fracture rate among the 3 groups with *COL1A2* mutations only. (**d**) Comparison of fracture rate between *COL1A1* and *COL1A2* mutations with all groups of mutations. (**e**) Comparison of fracture rate between *COL1A1* and *COL1A2* mutations with GS. (**f**) Comparison of fracture rate between *COL1A1* and *COL1A2* mutations with non-truncating mutations. The numbers in parentheses represent the sample numbers. GS: glycine substitution group; TG: truncating group; NTG: non-truncating group; OS: other missense group, ⁎: *p* \< 0.05, ⁎⁎: *p* \< 0.01, ⁎⁎⁎: *p* \< 0.001 (PNG 33 kb) High resolution image (EPS 1015 kb) Supplemental Fig 2Comparison of height. (**a**) Comparison of SDS of height among the 4 groups with *COL1A1* and *COL1A2* mutations. (**b**) Comparison of SDS of height among the 4 groups with *COL1A1* mutations only. (**c**) Comparison of SDS of height among the 3 groups with *COL1A2* mutations only. (**d**) Comparison of SDS of height between *COL1A1* and *COL1A2* mutations with all groups of mutations. (**e**) Comparison of SDS of height between *COL1A1* and *COL1A2* mutations with glycine substitutions. (**f**) Comparison of SDS of height between *COL1A1* and *COL1A2* mutations with non-truncating mutations. The numbers in parentheses represent the sample numbers. GS: glycine substitution group; TG: truncating group; NTG: non-truncating group; OS: other missense group; SDS: standard deviation score, ⁎: *p* \< 0.05, ⁎⁎: *p* \< 0.01, ⁎⁎⁎: *p* \< 0.001 (PNG 32 kb) High resolution image (EPS 1021 kb) Supplemental Fig 3Comparison of L1-L4 BMD and TBS. (**a**) Comparison of SDS of L1-L4 BMD among the 4 groups with *COL1A1* and *COL1A2* mutations. (**b**) Comparison of SDS of L1-L4 BMD among the 4 groups with *COL1A1* mutations only. (**c**) Comparison of SDS of L1-L4 BMD among the 3 groups with *COL1A2* mutation only. (**d**) Comparison of SDS of L1-L4 BMD between *COL1A1* and *COL1A2* mutations with all groups of mutations. (**e**) Comparison of SDS of L1-L4 BMD between *COL1A1* and *COL1A2* mutations with glycine substitutions. (**f**) Comparison of SDS of L1-L4 BMD between *COL1A1* and *COL1A2* mutations with non-truncating mutations. The numbers in parentheses represent the sample numbers, GS: glycine substitution group; TG: truncating group; NTG: non-truncating group; OS: other missense group; SDS: standard deviation score. ⁎: *p* \< 0.05 (PNG 40 kb) High resolution image (EPS 1177 kb) Supplemental Fig 4Positional effect of mutations on fracture rate. (**a**) Comparison of fracture rates among N-terminal pro-peptide, triple helix, and C-terminal pro-peptide mutations in *COL1A*1 and *COL1A2*. (**b**) Comparison of fracture rates among N-terminal pro-peptide, triple helix, and C-terminal pro-peptide mutations in *COL1A1* only. (**c**) Comparison of fracture rates between *COL1A1* and *COL1A2* mutations located on the triple helix. (**d**) Relationship between fracture rate and exon number for mutations located in *COL1A1* and *COL1A2*. (**e**) Relationship between fracture rate and exon number for mutations located in *COL1A1* only. (**f**) Relationship between fracture rate and exon number for mutations located in *COL1A2* only. The numbers in parentheses represent the sample numbers. N: N-terminal pro-peptide; Helix: triple helix; C: C-terminal pro-peptide. No significant differences nor correlations were observed in these analyses (PNG 31 kb) High resolution image (EPS 982 kb) Supplemental Fig 5Positional effect of mutations on height. (**a**) Comparison of SDS of height among N-terminal pro-peptide, triple helix, and C-terminal pro-peptide mutations in *COL1A*1 and *COL1A2*. (**b**) Comparison of SDS of height among N-terminal pro-peptide, triple helix, and C-terminal pro-peptide mutation in *COL1A1* only. (**c**) Comparison of SDS of height between *COL1A1* and *COL1A2* mutations located in the triple helix. (**d**) Relationship between SDS of height and exon number for mutations located in *COL1A1* and *COL1A2*. (**e**) Relationship between SDS of height and exon number for mutations located in *COL1A1* only. (**f**) Relationship between SDS of height and exon number for mutations located in *COL1A2* only*.* The numbers in parentheses represent the sample numbers. N: N terminal pro-peptide; Helix: triple helix; C: C terminal pro-peptide. No significant differences nor correlations were observed in these analyses (PNG 30 kb) High resolution image (EPS 999 kb) Supplemental Fig 6Positional effect of mutations on L1-L4 BMD. (**a**) Comparison of SDS of L1-L4 BMD among N-terminal pro-peptide, triple helix, and C-terminal pro-peptide mutations in *COL1A*1 and *COL1A2*. (**b**) Comparison of SDS of L1-L4 BMD among N-terminal pro-peptide, triple helix, and C-terminal pro-peptide mutations in *COL1A1* only. (**c**) Comparison of SDS of L1-L4 BMD between *COL1A1* and *COL1A2* mutations located in the triple helix. (**d**) Relationship between SDS of L1-L4 BMD and exon number for mutations located in *COL1A1* and *COL1A2*. (**e**) Relationship between SDS of L1-L4 BMD and exon number for mutations located in *COL1A1* only. (**f**) Relationship between SDS of L1-L4 BMD and exon number for mutations located in *COL1A2* only*.* A significant correlation was observed between L1-L4 BMD and location of mutations in *COL1A2* (*r*^2^= 0.74, *p* = 0.003). The numbers in parentheses represent the sample numbers. N: N-terminal pro-peptide; Helix: triple helix; C: C-terminal pro-peptide. No significant differences nor correlations were observed in (**a**-**e**) (PNG 33 kb) High resolution image (EPS 1025 kb) Supplementary Table 1(DOCX 12 kb)
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